Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 239,038 | 168,743 | 74,482 | 480,370 | 291,418 |
| Depreciation Amortization | 259,637 | 171,439 | 85,357 | 314,124 | 233,610 |
| Income taxes - deferred | -25,988 | -13,073 | -987 | -50,903 | -28,251 |
| Accounts receivable | 18,300 | 1,072 | -17,281 | -33,434 | -59,081 |
| Accounts payable and accrued liabilities | -7,095 | -6,436 | -8,541 | -20,427 | -26,531 |
| Other Working Capital | 12,067 | -59,424 | -48,092 | -102,380 | -140,769 |
| Other Operating Activity | 79,256 | 61,102 | 44,950 | 96,548 | 192,559 |
| Operating Cash Flow | $575,215 | $323,423 | $129,888 | $683,898 | $462,955 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -45,264 | -35,538 | -13,867 | -54,215 | -36,322 |
| PPE Investments | -157,351 | -118,630 | -79,144 | -318,528 | -240,205 |
| Net Acquisitions | -5,479 | -5,479 | N/A | -194,785 | -50,166 |
| Sale Of Investment | 39,470 | 12,359 | 7,502 | 6,667 | 3,953 |
| Other Investing Activity | -358 | -370 | -283 | -2,294 | -2,044 |
| Investing Cash Flow | $-168,982 | $-147,658 | $-85,792 | $-563,155 | $-324,784 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 976,783 | 741,200 | 300,882 | 776,353 | 333,034 |
| Debt Repayment | -1,316,990 | -987,344 | -292,482 | -851,676 | -530,909 |
| Common Stock Issued | 23,110 | 22,331 | 21,505 | 25,597 | 19,658 |
| Common Stock Repurchased | -119,051 | -18,265 | -9,351 | -24,155 | -24,016 |
| Other Financing Activity | -38,900 | -25,434 | -2,208 | -11,640 | -6,856 |
| Financing Cash Flow | $-475,048 | $-267,512 | $18,346 | $-85,521 | $-209,089 |
| Exchange Rate Effect | -4,025 | -11,729 | -8,387 | 8,044 | -4,680 |
| Beginning Cash Position | 284,480 | 284,480 | 284,480 | 241,214 | 241,214 |
| End Cash Position | 211,640 | 181,004 | 338,535 | 284,480 | 165,616 |
| Net Cash Flow | $-72,840 | $-103,476 | $54,055 | $43,266 | $-75,598 |
| Free Cash Flow | |||||
| Operating Cash Flow | 575,215 | 323,423 | 129,888 | 683,898 | 462,955 |
| Capital Expenditure | -157,351 | -118,630 | -79,144 | -318,528 | -240,205 |
| Free Cash Flow | 417,864 | 204,793 | 50,744 | 365,370 | 222,750 |